Neoadjuvant therapy for HER2-positive acantholytic squamous cell breast carcinoma: a case report-Reference-Cited by-同舟云学术

Neoadjuvant therapy for HER2-positive acantholytic squamous cell breast carcinoma: a case report

Published:2023-08 Issue:8 Volume:51 Page:
ISSN:0300-0605
Container-title:Journal of International Medical Research
language:en
Short-container-title:J Int Med Res

Author:

Cong Jia¹,Jo HyonSu²³,Zou Na⁴,Kong LingXin⁵,Ri HyokJu²³^ORCID

Affiliation:

1. Department of Breast Surgery, Dalian Women and Children's Medical Group, Dalian, People’s Republic of China

2. Department of Breast Surgery, The Second Hospital of Dalian Medical University, Dalian, People’s Republic of China

3. Department of General Surgery, The Hospital of Pyongyang Medical University, Pyongyang, D.P.R. of Korea

4. Department of Pathology, Dalian Women and Children's Medical Group, Dalian, People’s Republic of China

5. Department of Radiology, Dalian Women and Children's Medical Group, Dalian, People’s Republic of China

Abstract

HER2-positive acantholytic squamous cell carcinoma (ASCC) of the breast is exceptionally rare, and its clinicopathologic features are poorly understood. The impact of neoadjuvant therapy on HER2-positive breast ASCC is unclear. Here we report on a 58-year-old woman who was diagnosed with HER2-positive ASCC of the right breast, who underwent neoadjuvant treatment with albumin-paclitaxel, carboplatin, and trastuzumab, and surgery. Neoadjuvant therapy was effective, with no recurrence or metastasis after 1.5 years of postoperative follow-up.

Publisher

SAGE Publications

Subject

Biochemistry (medical),Cell Biology,Biochemistry,General Medicine

Link

http://journals.sagepub.com/doi/pdf/10.1177/03000605231187936

Reference20 articles.

1. Squamous cell carcinoma of the breast

2. Histopathological Variants of Cutaneous Squamous Cell Carcinoma: A Review

3. A rare acantholytic variant of squamous cell carcinoma of the maxilla

4. Acantholytic squamous cell carcinoma of the oral cavity: A rare entity